Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/195805
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Harrington, Kevin J. | - |
dc.contributor.author | Burtness, Barbara | - |
dc.contributor.author | Greil, Richard | - |
dc.contributor.author | Soulières, Denis | - |
dc.contributor.author | Tahara, Makoto | - |
dc.contributor.author | Castro, Gilberto de | - |
dc.contributor.author | Psyrri, Amanda | - |
dc.contributor.author | Braña, Irene | - |
dc.contributor.author | Basté, Neus | - |
dc.contributor.author | Neupane, Prakash | - |
dc.contributor.author | Bratland, Åse | - |
dc.contributor.author | Fuereder, Thorsten | - |
dc.contributor.author | Hughes, Brett G.M. | - |
dc.contributor.author | Mesía Nin, Ricard | - |
dc.contributor.author | Ngamphaiboon, Nuttapong | - |
dc.contributor.author | Rordorf, Tamara | - |
dc.contributor.author | Ishak, Wan Zamaniah Wan | - |
dc.contributor.author | Lin, Jiaxin | - |
dc.contributor.author | Gumuscu, Burak | - |
dc.contributor.author | Swaby, Ramona F. | - |
dc.contributor.author | Rischin, Danny | - |
dc.date.accessioned | 2023-03-22T15:59:46Z | - |
dc.date.available | 2023-04-11T05:10:31Z | - |
dc.date.issued | 2022-10-11 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://hdl.handle.net/2445/195805 | - |
dc.description.abstract | Purpose: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. Methods: Patients were randomly assigned (1:1:1) to pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy. Efficacy was evaluated in programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20, CPS ≥ 1, and total populations, with no multiplicity or alpha adjustment. Results: The median study follow-up was 45.0 months (interquartile range, 41.0-49.2; n = 882). At data cutoff (February 18, 2020), overall survival improved with pembrolizumab in the PD-L1 CPS ≥ 20 (hazard ratio [HR], 0.61; 95% CI, 0.46 to 0.81) and CPS ≥ 1 populations (HR, 0.74; 95% CI, 0.61 to 0.89) and was noninferior in the total population (HR, 0.81; 95% CI, 0.68 to 0.97). Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS ≥ 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. The objective response rate on second-course pembrolizumab was 27.3% (3 of 11). PFS2 improved with pembrolizumab in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.84) and CPS ≥ 1 (HR, 0.79; 95% CI, 0.66 to 0.95) populations and with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.86), CPS ≥ 1 (HR, 0.66; 95% CI, 0.55 to 0.81), and total (HR, 0.73; 95% CI, 0.61 to 0.88) populations. PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes. Conclusion: With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Patients responded well to subsequent treatment after pembrolizumab-based therapy. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1200/JCO.21.02508 | - |
dc.relation.ispartof | Journal of Clinical Oncology, 2022, vol. 41, num. 4, p. 790-802 | - |
dc.relation.uri | https://doi.org/10.1200/JCO.21.02508 | - |
dc.rights | (c) American Society of Clinical Oncology, 2022 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Anticossos monoclonals | - |
dc.subject.other | Chemotherapy | - |
dc.subject.other | Head cancer | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Monoclonal antibodies | - |
dc.title | Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 732810 | - |
dc.date.updated | 2023-03-22T15:59:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36219809 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
732810.pdf | 880.43 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.